Treatment
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications
Cancer Cell International 2024 March 12 [Link] Shan Ge, Yuwei Zhao, Jun Liang, Zhongning He, Kai Li, Guanghui Zhang, Baojin Hua, Honggang Zheng, Qiujun Guo 2, Runzhi Qi, Zhan Shi Abstract Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor…
Read MoreUV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial
European Journal of Cancer 2024 March 1 [Link] Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland Abstract Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine…
Read MoreThe highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Translational Oncology 2024 May [Link] Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti Abstract Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly…
Read MoreNivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
Tumori 2024 February 19 [Link] Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso Abstract Background:…
Read MorePegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial
JAMA Oncology 2024 February 15 [Link] Peter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L Ceresoli, Aaron S Mansfield, Anne Tsao, Kenneth J O’Byrne, Anna K Nowak, Jeremy Steele, Michael Sheaff, Chiung-Fang Shiu, Chih-Ling…
Read MoreMononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
Frontiers in Neurology 2024 January 25 [Link] Antonio Farina, Manon Escalere, Matthias Dion, Martin Moussy, Antoine Pegat, Macarena Villagrán-García, Perrine Devic, Anaïde Lamiral, Antoine Seyve, Karine Aure, Adrien Wang, Lucas Gorza, Nathalie Streichenberger, Thierry Maisonobe, Jerome Honnorat, Cristina Birzu, Dimitri Psimaras, David Weisenburger-Lile, Bastien Joubert Abstract Introduction: Mononeuritis multiplex is frequently related to vasculitic neuropathy…
Read MoreIs extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…
Read MoreBAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma
Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…
Read MoreA case of attempted transbronchial spigot insertion for fistulous pyothorax in the residual pleural airspace after pleurectomy/decortication for malignant pleural mesothelioma
Respirology Case Reports 2024 January 24 [Link] Ryo Miyata, Shoichiro Morizono, Tadashi Umehara, Aya Harada-Takeda, Go Kamimura, Masaya Aoki, Toshiyuki Nagata, Kazuhiro Ueda Abstract Pleurectomy/decortication for malignant pleural mesothelioma is a relatively recent surgical approach for which there is a dearth of information on complications, especially in the late postoperative period. A 70-year-old man was…
Read MoreImmunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Frontiers in Immunology 2024 January 8 [Link] Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio Abstract Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the…
Read More